SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated January 18, 2002
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
-----------
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F
--- ---
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
--- ---
Enclosure:
1. Invitation for the Full Year Results 2001 Presentation.
Investor Relations Novartis International AG
CH-4002 Basel
Switzerland
[NOVARTIS LOGO] Karen J. Huebscher, Ph.D.
Tel + 41 61 324 8433
Nafida Bendali
Tel + 41 61 324 3514
Sabine Moravi, MBA
Tel +41 61 324 8989
Silke Zentner
Tel +41 61 324 8612
Francisco Bouzas
Tel +41 61 324 2462
Fax +41 61 324 8444
Internet Address:
http://www.novartis.com
--------------------------------------------------------------------------------
- Full Year Results 2001 -
--------------------------------------------------------------------------------
The Executive Committee of Novartis has great pleasure in inviting you to the
presentation of the 2001 results and business developments. The meeting will
take place on
Thursday, February 7, 2002
At 1.30 PM for a 2.00 PM prompt start at the
Kongresszentrum in Basel
Messeplatz 21
Basel, Switzerland
-----------
Following the presentation, refreshments will be served.
We hope that you will be able to attend. Please find attached a reply form for
your convenience.
--------------------------------------------------------------------------------
- Reply form -
--------------------------------------------------------------------------------
[ ] I will attend the Basel Presentation on February 7, 2002
[ ] I will follow the presentation on the Internet
First name ____________________________________
Last name ____________________________________
Company ____________________________________
Address ____________________________________
____________________________________
Fax ____________________________________
E-mail ____________________________________
Please send your response by mail or fax no later than February 1, 2002 to:
Novartis International AG
Raquel Rodriguez
Lichtstrasse 35
CH-4002 Basel
Fax # +41 61 324 8444
E-mail: raquel.rodriguez@group.novartis.com
--------------------------------------------------------------------------------
- Full Year Results 2001 webcast and dial-in numbers -
--------------------------------------------------------------------------------
If you wish to follow our Full Year Results presentation as
a webcast on the Internet, please use the following link:
http://www.novartis.com/investors/index.shtml
---------------------------------------------
If you prefer to dial into the conference through a telephone line we also offer
the following dial-in numbers. The presentations will be available on the
website and least 1 hour prior to the start of the event.
Date: Thursday, February 7, 2002
Time: Advisable: dial-in 15 minutes before
2.00 p.m. Switzerland
1.00 p.m. UK
8.00 a.m. New York
Phone numbers: +41 (0) 848 22 41 11 Europe
+1 800 860 24 42 USA
Playback for 72 hrs after the call commencing
Date: Thursday, February 7, 2002
Time: 6.00 p.m. (Switzerland)
5.00 p.m. (UK)
12.00 p.m. (New York)
Phone numbers: +41 (0) 848 72 25 00 Europe
+1 877 344 75 29 USA
Code: 539#
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Novartis AG
Date: January 18, 2002 By: /s/ RAYMUND BREU
-------------------------
Name: Raymund Breu
Title: Chief Financial Officer